Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Fund Precision Medicine Technology Development at Syapse

CHICAGO (GenomeWeb) – Roche has agreed to support software vendor Syapse in the development of new analytics technologies with the goal of broadening access to precision medicine for cancer treatment.

The companies announced a multiyear collaboration today during the annual J.P. Morgan Healthcare Conference in San Francisco. Financial terms were not disclosed.

Syapse, a San Francisco-based maker of software to support precision cancer care, will work with Roche to create new analytics technologies on the existing Syapse platform. Roche is funding the work, which Syapse will deploy to its existing customer base of care providers and others looking to step up their precision medicine programs.

The partners said they have identified four focus areas of their initial work. They seek to: develop a "learning health system" to provide physicians with continually updated evidence at the point of care; help care providers adapt to value-based care by understanding the economic consequences of their decisions; study patient-reported outcomes as they affect quality of life; and better match patients to clinical trials.

The partnership leaves the door open to additional work, such as automating methods of measuring "real-world outcomes," according to the companies.

A Syapse spokesman indicated that genomics is a central part of this collaboration since the Syapse platform already organizes and analyzes both genomic and clinical data to inform decisions at the point of care.

"Roche and Syapse share a common vision of ensuring widespread access to precision medicine so we can dramatically improve patient care," Daniel O’Day, CEO of Roche's pharma division, said in a statement. "This collaboration supports that vision. By combining the pioneering platform from Syapse and Roche's expertise in oncology, we can bring personalized healthcare to many more patients and healthcare providers."

Syapse recently landed $30 million in new venture capital to push precision diagnostics and targeted therapeutics.